Trial Profile
A Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease: 2nd Switching Antiplatelet Agents
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Ticagrelor
- Indications Coronary artery disease; Thrombosis
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms SWAP-2
- Sponsors Daiichi Sankyo Inc
- 11 Dec 2013 Results published in the Journal of the American College of Cardiology.
- 20 Nov 2013 Results presented at the 86th Annual Scientific Sessions of the American Heart Association.
- 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.